- SELLAS Life Sciences (NASDAQ:SLS) is up 10% premarket on modest volume on the heels of its announcement that it plans to proceed with a pivotal Phase 3 clinical trial evaluating lead candidate galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) who have achieved complete remission after second-line antileukemic therapy.
- GPS has Fast Track and Orphan Drug status in the U.S. for the indication. The primary endpoint of the 116-subject open-label study will be overall survival (OS).
- GPS, licensed from Memorial Sloan Kettering Cancer Center, targets a protein called Wilms Tumor 1 (WT1) which plays a key role in cell growth.
Sellas Life Sciences to launch registrational study of galinpepimut-S in AML; shares up 10% premarket
Recommended For You
About SLS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SLS | - | - |
SELLAS Life Sciences Group, Inc. |